Cefiderocol MIC quality control ranges in iron-depleted cation-adjusted Mueller-Hinton broth using a CLSI M23-A4 multi-laboratory study design

Michael D Huband; Akinobu Ito; Masakatsu Tsuji; Helio S Sader; Kelley A Fedler; Robert K Flamm

doi:10.1016/j.diagmicrobio.2017.03.011

Cefiderocol MIC quality control ranges in iron-depleted cation-adjusted Mueller-Hinton broth using a CLSI M23-A4 multi-laboratory study design

Diagn Microbiol Infect Dis. 2017 Jun;88(2):198-200. doi: 10.1016/j.diagmicrobio.2017.03.011. Epub 2017 Mar 23.

Authors

Michael D Huband¹, Akinobu Ito², Masakatsu Tsuji², Helio S Sader³, Kelley A Fedler³, Robert K Flamm³

Affiliations

¹ JMI Laboratories, North Liberty, IA, USA. Electronic address: mike-huband@jmilabs.com.
² Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd., Toyonaka, Osaka, Japan.
³ JMI Laboratories, North Liberty, IA, USA.

PMID: 28410852
DOI: 10.1016/j.diagmicrobio.2017.03.011

Abstract

Cefiderocol (formerly S-649266) is a new catechol-substituted parenteral siderophore cephalosporin with potent in vitro antibacterial activity against Gram-negative isolates including multidrug-resistant strains. A recent study following CLSI M23-A4 quality control guidelines established cefiderocol MIC QC ranges against Escherichia coli ATCC 25922 (0.06-0.5 μg/mL) and Pseudomonas aeruginosa ATCC 27853 (0.06-0.5 μg/mL).

Keywords: Cefiderocol; M23; Quality control; S-649266; Siderophore cephalosporin.

MeSH terms

Anti-Bacterial Agents / pharmacology*
Cefiderocol
Cephalosporins / pharmacology*
Drug Resistance, Multiple, Bacterial
Escherichia coli / drug effects*
Humans
Iron / metabolism
Microbial Sensitivity Tests / methods
Pseudomonas aeruginosa / drug effects*
Quality Control

Substances

Anti-Bacterial Agents
Cephalosporins
Iron
Cefiderocol